
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Office of Inspector General's report on the FDA's oversight of clinical investigators' financial information.
The U.S. Department of Health and Human Services' Office of Inspector General has published a report, "The Food and Drug Administration's Oversight of Clinical Investigators' Financial Information," which can be found at:






